Cargando…

Tau PET imaging in neurodegenerative tauopathies—still a challenge

The accumulation of pathological misfolded tau is a feature common to a collective of neurodegenerative disorders known as tauopathies, of which Alzheimer’s disease (AD) is the most common. Related tauopathies include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), Down’s syndrome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leuzy, Antoine, Chiotis, Konstantinos, Lemoine, Laetitia, Gillberg, Per-Göran, Almkvist, Ove, Rodriguez-Vieitez, Elena, Nordberg, Agneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756230/ https://www.ncbi.nlm.nih.gov/pubmed/30635637 http://dx.doi.org/10.1038/s41380-018-0342-8

Ejemplares similares

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
por: Lemoine, Laetitia, et al.
Publicado: (2018)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
por: Murugan, N. Arul, et al.
Publicado: (2019)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
por: Saint-Aubert, Laure, et al.
Publicado: (2016)

Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [(18)F]THK5317 PET
por: Jonasson, My, et al.
Publicado: (2019)

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016)

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
por: Bucci, Marco, et al.
Publicado: (2021)

Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains
por: Malarte, Mona-Lisa, et al.
Publicado: (2022)

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2016)

Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
por: Chiotis, Konstantinos, et al.
Publicado: (2018)

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2019)

Cortical laminar tau deposits and activated astrocytes in Alzheimer’s disease visualised by (3)H-THK5117 and (3)H-deprenyl autoradiography
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases
por: Malarte, Mona-Lisa, et al.
Publicado: (2020)

Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer’s Tauopathy
por: Murugan, N. Arul, et al.
Publicado: (2021)

Integrated (18)F-T807 Tau PET, Structural MRI, and Plasma Tau in Tauopathy Neurodegenerative Disorders
por: Li, Cheng-Hsuan, et al.
Publicado: (2021)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease
por: Carter, Stephen F., et al.
Publicado: (2018)

A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease
por: Almkvist, Ove, et al.
Publicado: (2023)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer’s disease variants: AβPParc and PSEN1DE9
por: Lemoine, Laetitia, et al.
Publicado: (2020)

Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue
por: Lemoine, Laetitia, et al.
Publicado: (2015)

PET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies
por: James, Olga G., et al.
Publicado: (2015)

Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
por: Chiotis, Konstantinos, et al.
Publicado: (2015)

Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases
por: Nilson, Ashley N., et al.
Publicado: (2016)

Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?
por: Alavi Naini, Seyedeh Maryam, et al.
Publicado: (2015)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography
por: Schöll, Michael, et al.
Publicado: (2015)

Transcellular Spreading of Tau in Tauopathies
por: Demaegd, Koen, et al.
Publicado: (2018)

Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease
por: Vilaplana, Eduard, et al.
Publicado: (2020)

Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias
por: Murray, Melissa E, et al.
Publicado: (2014)

Are Tau Aggregates Toxic or Protective in Tauopathies?
por: Cowan, Catherine M., et al.
Publicado: (2013)

NMR Studies of Tau Protein in Tauopathies
por: Kitoka, Kristine, et al.
Publicado: (2021)

Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils
por: Zhou, Yang, et al.
Publicado: (2021)

Comparison of subtyping methods for neuroimaging studies in Alzheimer’s disease: a call for harmonization
por: Mohanty, Rosaleena, et al.
Publicado: (2020)

CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
por: Karami, Azadeh, et al.
Publicado: (2019)

Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges
por: Castellani, Rudy J., et al.
Publicado: (2019)

Tau PET following acute TBI: Off-target binding to blood products, tauopathy, or both?
por: Butler, Tracy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0l1cbp2l84kitptsclpfoor5k6